CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response

Abstract

Heightened effector function and prolonged persistence, the key attributes of Th1 and Th17 cells, respectively, are key features of potent anti-tumor Tcells. Here, we established exvivo culture conditions to generate hybrid Th1/17 cells, which persisted long-term invivo while maintaining their effector function. Using transcriptomics and metabolic profiling approaches, we showed that the enhanced anti-tumor property of Th1/17 cells was dependent on the increased NAD+-dependent activity of the histone deacetylase Sirt1. Pharmacological or genetic inhibition of Sirt1 activity impaired the anti-tumor potential of Th1/17 cells. Importantly, Tcells with reduced surface expression of the NADase CD38 exhibited intrinsically higher NAD+, enhanced oxidative phosphorylation, higher glutaminolysis, and altered mitochondrial dynamics that vastly improved tumor control. Lastly, blocking CD38 expression improved tumor control even when using Th0 anti-tumor Tcells. Thus, strategies targeting the CD38-NAD+ axis could increase the efficacy of anti-tumor adoptive Tcell therapy.